Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

Clinical Infectious Diseases

Volumn 42, Issue 5, 2006, Pages 657-668

  Talbot, George H ^a,i   Bradley, John ^b,c   Edwards Jr , John E ^d,e   Gilbert, David ^f   Scheid, Michael ^g   Bartlett, John G ^h  

^a Talbot Advisors   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTASTAPH; ANIDULAFUNGIN; ANTIINFECTIVE AGENT; AUREXIS; AUROGRAB; BAL 8557; BASILEA; BSYX A110; CEFTOBIPROLE; CETHROMYCIN; CS 023; DALBAVANCIN; DORIPENEM; FROPENEM; GARENOXACIN; HEAT SHOCK PROTEIN 90; ICLAPRIM; INH A21; MYCOGRAB; ORITAVANCIN; PLEUROMUTILIN; POSACONAZOLE; PPI 0903; PRULIFLOXACIN; RAVUCONAZOLE; RECOMBINANT ANTIBODY; RECOMBINANT HEAT SHOCK PROTEIN 90 ANTIBODY; RO 4908463; SB 275833; STAPHVAX; STAPHYLOCOCCUS VACCINE; TAK 599; TEFIBAZUMAB; TELAVANCIN; UNCLASSIFIED DRUG; VERONATE;

ACINETOBACTER BAUMANNII; CLINICAL TRIAL; DRUG INDUSTRY; DRUG RESEARCH; ESCHERICHIA COLI; HUMAN; INFECTION; KLEBSIELLA; LAW; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS; PUBLIC HEALTH;

EID: 33144473431     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499819     Document Type: Review

References (86)

1. Smolinski MS, Hamburg MA, Lederberg J, eds. Microbial threats to health: emergence, detection, and response. Washington, DC: The Institute of Medicine, 2003.
2. Diekema DJ, BootsMiller BJ, Vaughn TE, et al. Antimicrobial resistance trends and outbreak frequency. Clin Infect Dis 2004; 38: 78-85.
3. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38:1279-86.
4. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 2005; 5:115-9.
5. Wenzel RP. The antibiotic pipeline - challenges, costs, and values. N Engl J Med 2004; 351:523-6.
6. DeMaria A. Challenges of sexually transmitted disease prevention and control: no magic bullet, but some bullets would still be appreciated. Clin Infect Dis 2005; 41:804-7.
7. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6:427-30.
8. Shlaes DM, Projan SJ, Edwards JE. Antibiotic discovery: state of the state. ASM News 2004; 70:275-81.
9. Bush K. Why it is important to continue antibacterial drug discovery. ASM News 2004; 70:282-7.
10. Powers JH. Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis 2003; 16:547-51.
11. Sheridan C. Antiinfective biotechs face partnering gap. Nat Biotechnol 2005; 23:155-6.
12. Powers JH. Antimicrobial drug development - the past, the present, and the future. Clin Microbiol Infect 2004; 10(Suppl 4): 23-31.
13. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America, 2004.
14. The Protecting America in the War on Terror Act of 2005. 109th Cong. (24 January 2005): S 3.
15. The Biodefense and Pandemic Vaccine and Drug Development Act of 2005. 109th Cong. (17 October 2005): S 1873.
16. The Project BioShield II Act of 2005. 109th Cong. (28 April 2005): S 975.
17. The Infectious Diseases Research and Development Act of 2005. 109th Cong. (30 June 2005): H 3154.
18. American Society for Microbiology. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]. 2004.
19. Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr Opin Microbiol 2004; 7:466-76.
20. Farr-Jones S, Boggs AF. Antibacterial drug discovery and development: a 2004 snapshot. Waltham, MA: Decision Resources, 19 May 2004.
21. Page MGP. Cephalosporins in clinical development. Expert Opin Investig Drugs 2004; 13: 973-85.
22. Alekshun MN. New advances in antibiotic discovery and development. Expert Opin Investig Drugs 2005; 14:117-34.
23. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. National Nosocomial Infection Surveillance System Clin Infect Dis 2005; 41:848-54.
24. Davis KA, Moran KA, McAllister K, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11:1218-24.
25. Garzoni C, Emonet S, Legout L, et al. Atypical infections in tsunami survivors. Emerg Infect Dis 2005; 11:1591-3.
26. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multi-drug resistant Acinetobacter species and Stenotrophomonas species as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2):S104-13.
27. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002; 162: 1515-20.
28. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37:214-20.
29. Falagas ME, Kasiakou SK. Colistin: the revival of polymixins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
30. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11-25.
31. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin structure infection and complicated intra-abdominal infections. Clin Infect Dis 2005; 41(Suppl 5):S315-32.
32. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15:569-74.
33. Connolly JE Jr, McAdams HP, Erasmus JJ, et al. Opportunistic fungal pneumonia. J Thorac Imaging 1999; 14:51-62.
34. Denning DW Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
35. Denning DW Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004; 170:580-1.
36. Talbot GH, Huang A, Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 1991; 13:219-32.
37. Ohmagari N, Raad II, Hachem R, et al. Invasive aspergillosis in patients with solid tumors. Cancer 2004; 101:2300-2.
38. Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 2004; 47:263-76.
39. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety, and efficacy. Drugs 2004; 64: 1997-2020.
40. Johnson MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother 2003; 4:807-23.
41. Walsh TJ, Fiberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
42. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
43. Walsh TJ, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
44. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 1993; 119:353-8.
45. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-23.
46. Paterson DL, Ko W-C, Gottberg AV, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
47. Paterson DL, Ko W-C, Gottberg AV, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended spectrum β-lactamases. Clin Infect Dis 2004; 39:31-7.
48. Deere D, Burghoffer B, Gautier V, Petit J-C, Ariel G. Outbreak of multi-resistant Klebsiella oxytoca involving strains with extended spectrum β-lactamases and strains with extended spectrum activity of chromosomal β-lactamase. J Antimicrob Chemother 2004; 54: 881-8.
49. Kang C-I, Kim S-H, Park WB, et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48:4574-81.
50. Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a city-wide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002; 35:834-41.
51. Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on selection of antimicrobial therapy. Clin Infect Dis 2001; 32:1085-9.
52. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med 2005; 352:380-91.
53. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59-69.
54. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004; 24:111-8.
55. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
56. Schwaoer MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial co-resistance among extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005; 49:2137-9.
57. Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004; 39:55-60.
58. Woodford N, Teerno PM, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004; 48: 4793-9.
59. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710-21.
60. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
61. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for the development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002; 35:1139-46.
62. D'Agata EMC, Green WK, Schulman G, Li H, Tang Y-W, Schaffner W. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 2001; 32:23-9.
63. Bhavani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36:145-58.
64. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327-33.
65. Carmeli Y, Eliopoulos G, Mozaffari, E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162:2223-8.
66. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000; 19:915-25.
67. Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis 2003; 16: 135-43.
68. Foca MD. Pseudomonas aeruginosa infections in the neonatal intensive care unit. Semin Perinatol 2002; 26:332-9.
69. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002; 17:47-56.
70. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-40.
71. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S146-55.
72. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306-25.
73. Poole K. Efflux-mediated resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2004; 10:12-26.
74. Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/nnis/2003NNISReport_AJIC.PDF. Accessed 20 January 2005.
75. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48:4606-10.
76. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
77. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003; 2:321-32.
78. Smith AW. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 2005; 57:1539-50.
79. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States. Arch Intern Med 2005; 165:1756-61.
80. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40:562-73.
81. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11: 868-72.
82. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
83. Engemann JJ, Carmeli Y, Cosgrove SA, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among subjects with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8.
84. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9:978-84.
85. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39.
86. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003; 24:342-6.